Bacterial particles retard tumor growth as a novel vascular disrupting agent

被引:7
|
作者
Guo, Fengzhu [1 ,2 ,3 ,4 ]
Ji, Gaili [1 ,2 ,3 ]
Li, Qiqi [1 ,2 ,3 ]
Yang, Yun [1 ,2 ,3 ]
Shui, Lin [1 ,2 ,3 ]
Shen, Yuge [1 ,2 ,3 ]
Yang, Hanshuo [1 ,2 ,3 ]
机构
[1] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu 610041, Sichuan, Peoples R China
[3] Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China
[4] Sichuan Univ, Lung Canc Ctr, West China Hosp, Chengdu 610041, Sichuan, Peoples R China
基金
中国国家自然科学基金;
关键词
Bacterial particle; Vascular disrupting agent; Tumor microenvironments; Inflammatory cytokines; TARGETED THERAPY; CANCER; CELLS; ANGIOGENESIS; VEGF; RECRUITMENT; MECHANISMS; RESISTANCE; HYPOXIA;
D O I
10.1016/j.biopha.2019.109757
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Due to hypoxia and poor circulation in the tumor interior, malignant cells in solid tumors are resistant to traditional therapies. In the present study, we reported that bacterial particles (BactPs) functioned effectively in retarding tumor growth as a novel vascular disrupting agent. The BactPs were inactivated intact bacteria. Intravenous administration of BactPs extensively disrupted vessels in the tumor interior, but not in normal organs, and resulted in tumor hemorrhage and necrosis in six hours. We revealed that the extensive disruption of tumor vasculature was due to drastic changes in the inflammatory factors in mice sera and the tumor micro-environments, indicating the critical role of the host immune response to the BactPs. Furthermore, we showed that a combination of six inflammatory cytokines was capable of inducing tumor hemorrhage and necrosis, similar to the effects of the BactPs. Together, these results suggest that BactPs are a novel kind of tumor vascular disruptor with a promising potential for solid tumor treatment.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Phase 1 dose escalation trial of the novel vascular disrupting agent NPI-2358
    Mita, Monica
    Spear, Matthew A.
    Yee, Lorrin K.
    Papadopoulos, K. P.
    Heath, Elisabeth
    Romero, Ofelia
    Lloyd, G. Kenneth
    Cropp, Gillian
    Mita, Alain
    LoRusso, Patricia
    CANCER RESEARCH, 2008, 68 (09)
  • [32] Discovery of a Novel Vascular Disrupting Agent Inhibiting Tubulin Polymerization and HDACs with Potent Antitumor Effects
    Zhu, Huajian
    Tan, Yuchen
    He, Chen
    Liu, Yang
    Duan, Yiping
    Zhu, Wenjian
    Zheng, Tiandong
    Li, Dahong
    Xu, Jinyi
    Yang, Dong-Hua
    Chen, Zhe-Sheng
    Xu, Shengtao
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (16) : 11187 - 11213
  • [33] Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agent
    Benezra, M.
    Phillips, E.
    Tilki, D.
    Ding, B-S
    Butler, J.
    Dobrenkov, K.
    Siim, B.
    Chaplin, D.
    Rafii, S.
    Rabbany, S.
    Bradbury, M. S.
    LEUKEMIA, 2012, 26 (08) : 1771 - 1778
  • [34] Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agent
    M Benezra
    E Phillips
    D Tilki
    B-S Ding
    J Butler
    K Dobrenkov
    B Siim
    D Chaplin
    S Rafii
    S Rabbany
    M S Bradbury
    Leukemia, 2012, 26 : 1771 - 1778
  • [35] CHE202: A novel oral active microtubule depolymerizing vascular disrupting agent.
    Hogberg, Marita
    Rickardson, Linda
    Dahlstedt, Emma
    Gillner, Mikael
    Johansson, Tommy
    Romero, Ivan
    Smitt, Olof
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [36] Evaluation of the antitumor activity of NOV202, a novel microtubule targeting and vascular disrupting agent
    Rickardson, Linda
    Kutvonen, Emma
    Orasniemi, Satu
    Hogberg, Marita
    Kallio, Marko J.
    Rehnmark, Stefan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 1335 - 1351
  • [37] Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel
    Millward, Michael
    Mainwaring, Paul
    Mita, Alain
    Federico, Kristine
    Lloyd, G. K.
    Reddinger, Natasha
    Nawrocki, Steffan
    Mita, Monica
    Spear, Matthew A.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1065 - 1073
  • [38] Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent
    Lickliter, J. D.
    Francesconi, A. B.
    Smith, G.
    Burge, M.
    Coulthard, A.
    Rose, S.
    Griffin, M.
    Milne, R.
    McCarron, J.
    Yeadon, T.
    Wilks, A.
    Cubitt, A.
    Wyld, D. K.
    Vasey, P. A.
    BRITISH JOURNAL OF CANCER, 2010, 103 (05) : 597 - 606
  • [39] Phase I trial of NPI-2358 (a novel vascular disrupting agent) plus docetaxel
    Millward, M.
    Mita, A.
    Spear, M. A.
    Federico, K. C.
    Lloyd, G. K.
    Cropp, G.
    Mita, M.
    Mainwaring, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel
    Michael Millward
    Paul Mainwaring
    Alain Mita
    Kristine Federico
    G. K. Lloyd
    Natasha Reddinger
    Steffan Nawrocki
    Monica Mita
    Matthew A. Spear
    Investigational New Drugs, 2012, 30 : 1065 - 1073